Brief: Noxopharm Receives A$5.865 Mln R & D Tax Rebate Under Australian Govt's Research And Development Tax Incentive Scheme During FY21
06/01/2022 22:19
Jan 7 (Reuters) - Noxopharm:
* RECEIVES A$5.865 MILLION R & D TAX REBATE UNDER AUSTRALIAN
GOVERNMENT'S RESEARCH AND DEVELOPMENT TAX INCENTIVE SCHEME
DURING FY21
Source text for Eikon: ID:nASX7XqND1
Further company coverage: NOX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Noxopharm
See all newsBrief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential
Brief: Noxopharm Says New Data Confirms Cancer-Fighting Potential
Brief: Noxopharm Appoints Dr Olivier Laczka As New CEO
Brief: Noxopharm Ltd Announces Resignation Of Chief Executive Officer